Impact of variable CYP genotypes on breast cancer relapse in patients undergoing adjuvant tamoxifen therapy

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 6, 2014, Pages 1181-1188

  Mwinyi, Jessica ^a   Vokinger, Kerstin ^a   Jetter, Alexander ^a   Breitenstein, Urs ^b   Hiller, Christian ^a   Kullak Ublick, Gerd A ^a   Trojan, Andreas ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Breast Center Zurich   (Switzerland)

Author keywords

Breast cancer; Drug metabolism; Genetic polymorphisms; Relapse free time; Tamoxifen; Therapy efficacy

Indexed keywords

AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DEXTROMETHORPHAN; DEXTRORPHAN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CYP2B6 GENE; CYP2C19 GENE; CYP2C9 GENE; CYP2D6 GENE; DNA POLYMORPHISM; ENZYME ACTIVITY; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; METABOLIC ACTIVITY ASSAY; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; URINARY EXCRETION;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; ISOENZYMES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, GENETIC; TAMOXIFEN;

EID: 84903819422     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2453-5     Document Type: Article

References (26)

1. Abdel-Rahman SM, Leeder JS, Wilson JT, Gaedigk A, Gotschall R, Medve R, Liao S, Spielberg SP, Kearns GL (2002) Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 42:24-29 (Pubitemid 34038366)
2. Baldwin RM, Ohlsson S, Pedersen RS, Mwinyi J, Ingelman-Sundberg M, Eliasson E, Bertilsson L (2008) Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. Br J Clin Pharmacol 65:767-774 (Pubitemid 351535091)
3. Blake MJ, Gaedigk A, Pearce RE, Bomgaars LR, Christensen ML, Stowe C, James LP, Wilson JT, Kearns GL, Leeder JS (2007) Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin Pharmacol Ther 81:510-516 (Pubitemid 46452306)
4. Ducharme J, Abdullah S, Wainer IW (1996) Dextromethorphan as an in vivo probe for the simultaneous determination of CYP2D6 and CYP3A activity. J Chromatogr B Biomed Appl 678:113-128 (Pubitemid 26114747)
5. Frank D, Jaehde U, Fuhr U (2007) Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 63:321-333 (Pubitemid 46399125)
6. Fuhr U, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther 81:270-283 (Pubitemid 46174825)
7. Furr BJ, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-205 (Pubitemid 14015738)
8. Gaedigk A, Ndjountche L, Divakaran K, Bradford LD, Zineh I, Oberlander TF, Brousseau DC, McCarver DG, Johnson JA, Alander SW, Riggs KW, Leeder JS (2007) Cytochrome P4502D6 (CYP2D6) gene locus heterogeneity: characterization of gene duplication events. Clin Pharmacol Ther 81:242-251 (Pubitemid 46178274)
9. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234-242
10. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318
11. Lum DW, Perel P, Hingorani AD, Holmes MV (2013) CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. PLoS ONE 8:e76648
12. Lyon E, Foster JG, Palomaki GE, Pratt VM, Reynolds K, Sabato MF, Scott SA, Vitazka P (2012) Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy. Genet Med 14:990-1000
13. Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, Eichelbaum M, Schwab M, Brauch H (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89:708-717
14. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104:1264; author reply 1266-1268
15. Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Michael Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonne AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE (2014) CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations. Clin Pharmacol Ther 95(2):216-227
16. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452-460
17. Ratain MJ, Nakamura Y, Cox NJ (2013) CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality. Clin Pharmacol Ther 94:185-187
18. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thurlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 104:441-451
19. Schroth W, Antoniadou L, Fritz P, Schwab M, Muerdter T, Zanger UM, Simon W, Eichelbaum M, Brauch H (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193 (Pubitemid 350232249)
20. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bolander J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436
21. Sim SC, Ingelman-Sundberg M (2013) Update on allele nomenclature for human cytochromes P450 and the Human Cytochrome P450 Allele (CYP-allele) Nomenclature Database. Methods Mol Biol 987:251-259
22. Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L, Ingelman-Sundberg M (2006) A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther 79:103-113 (Pubitemid 43069582)
23. Stanton V, Jr. (2012) Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104:1265-1266; author reply 1266-1268
24. Steijns LS, Van Der Weide J (1998) Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication. Clin Chem 44:914-917 (Pubitemid 28213128)
25. Trojan A, Vergopoulos A, Breitenstein U, Tausch C, Seifert B, Joechle W (2013) CYP2D6 phenotype indicative for optimized antiestrogen efficacy associates with outcome in early breast cancer patients. Cancer Chemother Pharmacol 71:301-306
26. Zeng Z, Liu Y, Liu Z, You J, Chen Z, Wang J, Peng Q, Xie L, Li R, Li S, Qin X (2013) CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis. Cancer Chemother Pharmacol 72:287-303